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Dimethoxyethyl Phthalate: Embryopathy,
Teratogenicity, Fetal Metabolism and
the Role of Zinc in the Rat*
by M. R. Parkhie,t* M. Webbt and
M. A. Norcross**
A single intraperitoneal injection (0.6 ml/kg) ofdimethoxyethyl phthalate (DMEP) was given
to groups of Wistar strain rats on day 10, 11, 12, 13 or 14 ofgestation. Control rats received 0.6
ml/kg of physiological saline intraperitoneally.
In phthalate-treated rats, embryopathy was manifested by a high incidence (12-79%) of fetal
deaths and fetal resorptions. Fetotoxic effects were expressed by a significant reduction in fetal
weights. Hydrocephalus interna, a congenital malformation ofthe brain, was caused by DMEP.
Congenital skeletal deformities (66-96%), with multiple skeletal (14-64%) and appendicular
malformations (25-57%), were also induced by DMEP. Control rats exhibited no congenital
malformations of the brain and no appendicular or multiple skeletal deformities.
DMEP caused a significant decrease in the zinc content of the fetus.
Fetoplacental metabolism 1 and 4 hr after intravenous administration of14C-DMEP suggested
rapid transfer of the parent compound to the fetus across the placenta and that DMEP is a
teratogenic moiety. The possible role of zinc in phthalate-induced teratogenesis in rats is also
discussed.
Introduction
Plastics have become an integral part of our
everyday lives. Phthalate esters are plasticizers
widely used in the manufacture of plastics (1). In
the United States, an estimated one billion pounds
of phthalate esters are produced annually (2, 3).
There are approximately 20 different phthalate
compounds sold as vinyl plasticizers, and one ofthe
most toxic of these is dimethoxyethyl phthalate
(DMEP) (1-3).
Phthalate esters are found in the composition of
floor tiles, various types of home furnishings,
waterproof clothing, industrial tubing, food wrap-
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ping materials (4, 5), and a variety of medical and
paramedicaldevices, includingheartvalves, vascular
grafting material, intrauterine devices, catheters,
dialyzing units, blood sets and disposable syringes.
Residues ofphthalates have been found in milk (6),
human tissues and blood plasma (7), bovine tissues
and the hearts of dogs, rabbits and rats (8).
Phthalates, in general, are colorless, high-boiling
liquids, soluble in organic solvents butimmiscible in
water, and they are degraded very slowly in the
ambient environment. Diethylhexyl phthalate
(DEHP), for example, closely resembles organo-
chlorine pesticides (DDT, PCB) in rate of uptake,
storage, and biomagnification in avariety ofaquatic
organisms (9).
The U.S. Department of Health and Human
Services, particularly the Food and Drug Adminis-
tration (4, 10) and the National Institute of Envi-
ronmental Health Sciences (11-13) has, therefore, a
continuinginterestandconcernregardingthesafety
of phthalates. This concern is reflected in the
sponsoring of conferences on phthalate esters in90
1972 (3, 4, 9, 13) and in 1981. Several reviews
(14-23) presented the toxicity of phthalate esters.
Although DMEP has been shown to be one of the
most toxic phthalates, little is known regarding the
teratogenicity caused by a single maternal injection
of DMEP during the organogenetic period in the
rat.
Dietary supplementation of zinc has prevented
teratogenic effects in rats induced by the maternal
administration of a chelating agent, ethylenedi-
aminetetraacetic acid (24). Dietary deprivation of
zinc, on the other hand, could induce embryopathic
and teratogenic effects in the rat, which was
otherwise resistant to the teratogenicity ofEM-12,
astableanalogofthalidomide(25). Althoughphthalate
esters bear similarities to thalidomide in inducing
congenital malformations in the chick embryo (26),
the role ofzinc, if any, in phthalate-induced terato-
genicity has not been reported.
Metabolism studies on phthalates using radio-
tracer techniques have been conducted in adult rats
(27-31). There is only one report concerning mater-
nalfetal transfer ofradiolabeled phthalates. It deals
with 14C-DEHP and diethyl phthalate (32). Fetal
metabolism of 14C-DMEP, however, is unknown.
The present studies, therefore, were designed to
determine whether (a) maternal administration in
rats of a single dose of DMEP during the organo-
genetic period induces embryopathic, fetotoxic or
teratogenic effects; (b) multiple congenital skeletal
malformations significantly higher than that of the
control could be induced by DMEP; (c) uptake of
65Zn by and the zinc content in the fetus are altered
by administration ofDMEP; and (d) DMEP reaches
the fetus as a metabolite or as the unaltered parent
compound.
Materials and Methods
Teratological Studies
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with each male in a separate cage. The dropping of
the mating plug from the female on the morning
following mating was counted as day zero of the
pregnancy, at which time the females were allo-
cated to control and treatment groups. All animals
had free access to a high protein pelleted rat diet
(suppliedbyBPNutrition, Stepfield, Witham, Essex,
England) and water and were housed in a temper-
ature-controlled (22 + 2°C) animal facility.
DMEP ofanalyticalgrade was administered intra-
peritoneally (IP) at a dose of0.6 ml/kgbody weight
on day 10, 11, 12, 13 or 14 ofgestation. The control
animals received the same volume (0.6 ml/kg) of
physiological saline intraperitoneally. The number
of animals in each treatment group is presented in
Table 1.
Pregnant rats were anesthetized by chloroform
on day 20, and the fetuses were removed by cesar-
ian operation. More than half of the fetuses were
assigned for evaluation of skeletal abnormalities
(33, 34); the rest were assigned for detection of
organ malformations. The fetuses were prepared
for evaluation of soft tissue abnormalities after
fixationin Bouins fluid for one week (35) and then in
70% ethanol for 5 days. Wilson's technique was
used for sectioning the fetuses and to evaluate
gross organ pathology (36). The fetuses were pre-
pared for evaluation of the skeletal abnormalities
by the modified rapid clearing technique using the
KOH-Alizarin Red S method ofStaples and Schnell
(37). Modifications included using 70% industrial
methylated spirit (ethanol 94.5%; methanol 4.0%,
water 1.5% vlv) in place of ethanol for fixation,
leaving fetuses for 3-4 days in 1% KOH containing
0.01% Alizarin Red S stain for maceration and
staining and keeping fetuses in clearing fluid for 2
to 3 days before transferring to an ethanol:glycerol
(1:1, vlv) mixture for evaluation. The skeletous
were evaluated and were classified as normal or
retarded (38, 39).
Outbred female rats of the Wistar strain weigh-
ing 240-280 g were used. One female was placed
Table 1. Fetotoxicity of DMEP iii rats: reduction in fetal weight.
Treatmenta No. of animals No. offetuses Mean fetal weight (± SEM), g d (p = 0.01), gb
Normal saline controls 17 157 4.09 ± 0.049
DMEP-10 19 49 2.87 ± 0.095c 0.156
DMEP-11 14 137 2.78 ± 0.027c 0.105
DMEP-12 12 113 3.04 ± 0.062c 0.141
DMEP-13 10 123 2.99 ± 0.029c 0.136
DMEP-14 15 102 3.34 ± 0.058c 0.215
aThe number after DMEP refers to the day ofgestation on which DMEP was injected. bMinimum weight difference required for the mean fetal weight of the treated rats to be significantly different from that of the
controls at p = 0.01 using Dunnetts test.
cReduction in fetal weight was highly significant (p < 0.01).TERATOGENICITY OF DIMETHOXYETHYL PHTHALATE
Uptake of 65Zn by and Zn Content in
the Placenta and Fetus
DMEP or physiological saline was injected IP on
day 13 of gestation at 0.6 ml/kg 4 hr prior to the
administration ofcarrier-free 65ZnCl2 in the coccyg-
eal vein at a dose of 15 ,Ci/ml per kilogram ofbody
weight. The animals were sacrificed bydecapitation
at 15 min, 1 hr and 4 hr after administration ofthe
radiotracer zinc. The uptake of65Zn was measured
with a Packard autogamma counter. The concen-
trations of zinc in the placental and fetal tissues
were measured by atomic absorption spectrometry
with a method (40) which was reliable and repeat-
able to 0.2 ppm ofzinc. This experiment included 24
pregnant female rats, with four rats at each time
period within a treatment group.
Fetoplacental Metabolism of '4C-DMEP
14C-DMEP, specificactivityO.912mCi/mmole (2.025
x107 DPM/mmole), was prepared from [carbonyl
'4C] phthalic acid (supplied by Radiochemical Cen-
tre, Amersham, Bucks, England). Radiochemical
purity of the labeled 14C-DMEP was : 99% as
confirmed by gas-liquid and thin-layer chromatog-
raphy. Chemical identity was confirmed by NMR
and GC/MS.
Rats were injected intravenously on day 13 of
gestation with 1C-DMEP or physiological saline at
0.6ml/kgbodyweight, andtheanimals weresacrificed
by decapitation at 1 and 4 hr after treatment. Each
treatment group had three animals. Placentae and
fetuses were dissected out. For measurement of
total phthalate concentration, pooled portions of
placental (0.33 ± 0.10 g) and fetal tissues (0.50
0.12 g) were dissolved in 1 ml Soluene and 10 ml of
Instagel (both obtained from Packard Instrument
Co.). For acid and neutral extractions of DMEP,
portions of the placentae (0.40 ± 0.08 g) and the
fetuses (0.42 ± 0.18 g) were homogenized with 1 ml
of 0.9% NaCl in a ground glass homogenizer. The
homogenates were extracted threetimes with ethyl
acetate (2.5 ml). The extractions were separated
into organic and aqueous phases by centrifugation
(4000 g, 5 min). The residual aqueous phase was
acidified to pH 1.0 with 2N H2SO4 and then re-
extracted with ethyl acetate. The neutral and acid
extracts were made to 10 ml with ethyl acetate. A
portion (5 ml) of each extract was transferred to a
scintillation vial and wasevaporated under a stream
ofN2 at 37°C to a volume of
- 1 ml before adding 10
ml ofInstagel for counting. The chemiluminescence
of the samples was minimized by storing the sam-
ples in a dark, cold storage room for 4-7 days.
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Counts, counting efficiency, and the original weight
ofthe sample were used to calculate the radioactiv-
ity ofeach specimen in terms ofdisintegrations per
minute per gram oftissue. These values were used
in conjunction with specific activity of injected
'4C-DMEP to estimate molar concentrations ofthe
teratogen in the fetus and the placenta.
Statistical Procedures
The reduction in mean fetal weight following
administration of DMEP was compared with the
normal saline controls by using Dunnett's proce-
dure (41). Chi-square with Yates's continuity cor-
rection (42) was used to testthe hypothesis that the
percentages of dead and/or resorbed fetuses are
equal in treatment and control groups and to com-
parethepercentages ofskeletallymalformedfetuses
with the control. Since the expected frequencies of
the congenital deformities ofthe brain were small,
Fisher's exact test was used to test these data.
Student's t-test was used to compare the mean
uptake of65Zn by and the Zn content ofthe placen-
tae and the fetuses.
Results
Embryopathy, Fetotoxicity and
Teratogenicity of DMEP
Maternal administration ofDMEP in rats caused
asignificant (p < 0.01)reductioninthemeanweight
of living fetuses as compared to the corresponding
value for the physiological saline-treated controls
(Table 1). A single injection of DMEP induced a
pronounced (p < 0.01)fetotoxicityduringtheorgano-
genetic period regardless of the day of injection.
Thefetotoxic (Table 1) andthe embryopathic (Table
2) effects were greater during the early stages
(days 10 or 11 of gestation) of organogenesis than
during the later stages (days 12, 13 or 14 of gesta-
tion).
Embryopathic effects were evaluated bypercent-
age ofdead and resorbed fetuses (Table 2). Repro-
ductive toxicity of DMEP, in this regard, was four
to seven times higher upon injection on day 10 of
gestation as compared to days 11-14; 79% of the
fetuses were dead and resorbed following maternal
administration ofDMEP on day 10. Intraperitoneal
administration of normal saline to pregnant rats
resulted in fetal death and resorptions in 7.6% of
fetuses.
In comparison to controls, DMEP induced higher
rates ofcongenital deformities ofthe brain. None of
the fetuses from the control group exhibited hydro-Table 2. Embryopathic effects of DMEP in rats.
Total Number (%)
Treatment No. of rats implantations fetuses, dead or resorbed p valuesa
Normal saline controls 17 170 13 (7.6)
DMEP-10 19 229 180 (78.6) <0.0001
DMEP-11 14 175 38 (21.7) 0.0004
DMEP-12 12 141 28 (19.9) 0.0027
DMEP-13 10 139 16 (11.5) 0.3358
DMEP-14 15 121 19 (15.7) 0.0483
aThe level ofprobability at which percent ofdead or resorbed fetuses following administration ofDMEP differed significantly from
that of the control by the chi-square test.
cephalus interna, a malformation of the CNS, as
opposed to a 13-26% rate ofmalformation in DMEP-
treated animals (Table 3).
The incidence of congenital skeletal malforma-
tions caused by DMEP is presented in Table 4.
Control rats exhibited an 18% incidence of skeletal
malformations whereas DMEP-induced skeletal
deformities were found in 66-96% of the fetuses.
This rate of skeletal dysmorphogenesis was 3.5- to
5-fold higher than that in the controls. Fetuses in
the control group showed no multiple malforma-
tions or appendicular dysmorphogenesis, while ma-
ternal administration of DMEP caused congenital
multiple skeletal malformations in 14-64% of the
fetuses and appendicular deformities in 25-57% of
the fetuses. Malformations inthe appendicularfibula
wererepresentedbyitsretardation, orbyitsabsence.
DMEP caused significantly higher (p < 0.005) rates
ofcongenital skeletal deformities and multiple mal-
formations in fetuses at all stages of gestation.
Malformations in the fibula were observed upon
administration of DMEP on day 12 or 13. The
skeletal deformities induced by DMEP included
complete loss ofthoracic ribs, their lack ofarticula-
tion from the spinal column and forked ribs with
bending, cracking and cessation of the vertebral
column at the lumbar or at the lower sacral region
and the appendicular deformities as represented by
the absence or marked shortening of the fibula.
Adverse Effect of DMEP on
Maternal-Fetal Zinc Metabolism
The uptake of65Zn by placentae and fetuses and
the zinc content in these tissues 1 hr post adminis-
tration of 65Zn are presented in Figures 1 and 2.
There was no significant difference (p < 0.05) in
65Zn uptake of the placentae and fetuses and the
placental zinc content between DMEP and physio-
logical saline treated animals. Fetal zinc content of
ratstreated with DMEP was, however, significantly
lower (p < 0.01) than ofthose treated with physio-
logical saline. The uptake and content of zinc in
placentae and fetuses in other treatment groups (15
min and 4 hr) were not significantly different from
the control.
Fetoplacental Metabolism
of 14C-DMEP
14C-DMEP activity associated with the placenta
and the fetus differed with respect to extraction
(Table 5). Placental activity was associated mostly
with the acidic metabolic products, since less than
10% (mean 6.4 + 0.8) of the total activity was
extractable fromtheneutralhomogenates withethyl
acetate; while the remainder was recovered from
the tissue residue after acidification. In contrast,
31-44.0% (mean 37.3 + 4.5) of the fetal activity
Table 3. Congenital malformation of the brain produced by DMEP in rats.a
No. of fetuses % fetuses
Treatment No. of rats Examined Malformed malfonned p valuesb
Normal saline controls 17 26 0
DMEP-10 19 14 2 14.3 0.117
DMEP-11 14 45 6 13.3 0.057
DMEP-12 12 55 13 23.6 0.004
DMEP-13 10 30 4 13.3 0.075
DMEP-14 15 39 10 25.6 0.004
aHydrocephalus interna.
bFishers exact test was used for these data.
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Table 4. Congenital skeletal malformations caused by DMEP in rats.
Gestational age (days) at administration of dimethoxyethyl phthalate
Variables Saline controls 10 11 12 13 14
Fetuses examined 131 35 92 58 93 63
Fetuses malformed 23 31 61 50 89 57
Malformations, % 17.5 88.6 65.9 85.9 96.0 90.6
Significance (p)8 - <0.005 <0.005 <0.005 <0.005 <0.005
Fetuses multiple with
malformations (no.) 0 21 13 37 31 27
Multiple malformations, % 0 60.0 14.1 63.7 33.3 42.8
Significance (p)a - <0.005 <0.005 <0.005 <0.005 <0.005
Fetuses showing absence or
retardation of fibula (no.) 0 0 0 33 23 0
% of fetuses showing
malformations offibula 0 0 0 56.9 24.7 0
aSignificance denotes the level ofp value at which percent malformations differs significantly from the control by Yate's continuity
correction of chi-square test.
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FIGURE 2. Mean uptake of 65Zn by and the mean zinc content
(,uglg wet tissue) in the fetus 1 hr following administration
of 6Zn.
FIGURE 1. Mean uptake of 'Zn by and the mean zinc content
in 1 g ofplacenta 1 hr following administration of 'Zn. Rats
were pretreated with CMEP or physiological saline (PS) 4
hr prior to 6Zn administration. Zinc content is in ,ug/g
wet tissue. SEM is the standard error of the mean value
based on four rats per treatment group. NS stands for not
significantly (p>0.05) different from PS group.
could be extracted, presum-^ly as the unchanged
diester, from the neutral homogenates with ethyl
acetate 4 hr following administration of DMEP.
These preliminaryresults suggest, therefore, that
the unmetabolized DMEP is transferred rapidly
across the placenta to the fetus and the DMEP may
be the teratogenic moiety.
Discussion
Teratogenicity of DMEP
The reported fetal deaths and resorptions caused
by a single maternal administration of DMEP on
day 10 of gestation in rats (Table 2) are in general
agreement with the embryotoxicity resulting from
multiple administrations ofDMEP (22). Asignificant
(p < 0.01) reduction in fetal weight (Table 1) has
also been observed with otherphthalate esters such
as DEHP and dibutyl phthalate in rats (43) and in
mice (44).
DMEPhasbeen shown to bethe mostembryo- and
fetotoxic member of the phthalate ester family (3,
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I cLTable 5. Metabolism of "4C-DMEP in placental and fetal tissues of the rat.
DMEP concentration, nmole/g wet tissue
Time after
Rat no. Tissue administration, hr Total Neutral extract % DMEP
1 Placenta 1 2796.4 100.7 3.6
1 Fetus 1 1640 848.3 51.7
2 Placenta 1 556.2 43.1 7.8
2 Fetus 1 368 101 27.4
3 Placenta 4 396 30 7.6
3 Fetus 4 45.4 14 30.8
4 Placenta 4 326.4 17.6 5.4
4 Fetus 4 23.6 10.4 44.1
5 Placenta 4 376 29 7.7
5 Fetus 4 40.9 13.3 32.5
X = 6.4 ± 0.8
X = 37.3 ± 4.5
16, 20). In part, this may be due to its high aqueous
solubility compared to other phthalate esters, al-
though the aqueous solubility ofall phthalate esters
is extremely low. DMEP, for example, is about 143
times (0.73 ml/100 ml H20) more soluble in water
than DEHP (0.0051 ml/100 ml H20) and is the most
soluble phthalate ester (3, 21). Fetal deaths and
resorptions caused by DMEP were as high as 79%
upon a single injection on day 10 ofgestation (Table
2).
Congenital malformations of the brain involving
hydrocephalus interna similar to those caused by
DMEP (Table 3) have also been induced by dietary
deficiency of zinc in rats (45-51). This is the first
report to document hydrocephaly caused by the
maternal administration of DMEP in rats.
Phthalate esters have been studied for their con-
genitalskeletaldysmorphogeneticeffectsinrodents,
but in this regard, these studies are the first to
report skeletal malformations following a single
injection ofDMEP. Phthalate esters are considered
compounds related to thalidomide (26). Congenital
multiple skeletal malformations and appendicular
dysmorphogenesis, which are considered "typical"
ofthethalidomide syndrome (39), havebeendifficult
to produce in rats. These studies are the first,
however, to report congenitalmultiple skeletalmal-
formations and appendicular dysmorphogenesis fol-
lowing maternal administration ofDMEP. Congen-
ital multiple skeletal malformations upon a single
intravenous maternal administration ofthalidomide
were also reported in our laboratory for the first
time (52).
Intraperitoneal administration of sterile normal
saline to pregnant animals resulted in some dead
and resorbed fetuses and also caused skeletal mal-
formations in control animals. Such effects have
been reported earlier (53). The reproductive toxic-
ity of DMEP, however, was several times higher
than the normal saline control. The teratogenic
effects of DMEP reported here have greater sig-
nificance than the results where teratogenicity of
phthalates is compared to untreated controls (22).
The malformations reported here are several hun-
dredfold higher than the sporadic malformations
found in rats, and are, therefore, due to the terato-
genicity ofDMEP. Major skeletal malformations in
rats occur at a frequency of0.41% (54), while those
caused by DMEP were 161-234 times higher than
this background level (Table 4). Craniofacial organ
deformities such ashydrocephaly occursporadically
in rats at a frequency of0.0506% (54), while DMEP
induced this CNS malformation (Table 3) in 13-26%
of the fetuses (257-514 times higher than the spo-
radic occurrence).
Role of Zinc in DMEP-Induced
Teratogenesis
The conclusion that DMEP alters zinc metabo-
lism in rats is based upon significantly (p
- 0.01)
decreased zinc content in the fetuses of DMEP-
treated rats as compared to that in the controls
(Fig. 2).
Pregnant rats cannot mobilize zinc sufficiently
from theirbody stores including that from the liver
and bone (50, 51), to supply the needs of their
fetuses. As aresult ofthis insufficient zinc supply, a
transient deficiency ofzincmayhavebeenproduced
following DMEP administration which, in turn, is
reflected by the decreased zinc content in the fetal
tissue. The teratogenic effects reported here are in
agreement with those caused by the decreased zinc
content in fetuses when rats were placed on zinc-
deficient diets during gestation (51).
Permeability of the placenta to zinc increases
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afterday 18 ofgestation (55). However, this has not
negated the validity of the results reported here
because fetal zinc concentrations relate to maternal
administration of DMEP or of physiological saline
on day 13 ofgestation. The fetal zinc concentration
(micrograms per gram ofwet tissue) reported here
is far lower than that reported by Hurley and
Swenerton (51) in 19- and 21-day-old fetuses. This
may be due to the increased permeability of the
placentato zinc after day 18 ofgestation and due to
maternal supplementation of dietary zinc at 100
ppm, as well as other factors (54).
The results ofthe fetoplacental metabolic studies
of zinc (Figs. 1 and 2) are also in agreement with
the pharmacokinetic aspects ofplacentaltransfer of
drugs using a single compartment model for dam
and fetus, and in agreement with the first-order
kinetics described by Levy and Hayton (56).
The adverse effects ofDMEP on zinc metabolism
andassociatedfetalanomaliesreportedhere(Tables
1-4, Figs. 1, 2) permit one to draw an analogy
between the phthalate-induced testicular damage
in rats and the associated adverse effects on zinc
metabolismcausedbyphthalates(57, 58). Theauthors
postulate that the protection provided by zinc in
phthalate-induced testicular damage (57, 58) may
beanalogous totheprotectionofferedbyzincagainst
certain teratogens in rats (24). Singh et al. (32)
reported that first order kinetics describe the elim-
inationof14C-labeledphthalatesfrommaternalblood,
amniotic fluid and fetal tissue with time. Also, zinc
(59) and phthalates (32) follow, in general, a similar
time course and concentration kinetics in maternal
bloodplasmaandfetaltissue. Therefore, theauthors
propose a role ofzinc in DMEP-induced teratogen-
esis in rats.
The reduced content of zinc in the target organ,
thefetus(Fig. 2), followingadministration ofDMEP,
may be due to the rapid turnover rate of zinc
following administration of phthalates (57, 58).
Coadministration of zinc was found to offer a sub-
stantial measure of protection against testicular
atrophy and loss oforgan weight caused by dibutyl
phthalate (57).
The protective effect, ifany, ofcoadministration
ofzincandtheunderlyingmechanismofzincagainst
the fetotoxic and teratogenic effects of DMEP is
unknown, as is the protective mechanism of zinc
therapy in phthalate-induced testicular atrophy.
Therearemanycommonparallels, however, between
congenital abnormalities caused by zinc deficiency
in rats (45, 47-50, 60, 61) and those produced by
DMEP (Tables 1-4). These include the manifesta-
tion of fetotoxicity by a marked reduction in fetal
weight (Table 1); embryopathy by fetal resorption
(Table 2); congenital malformations ofthe brain (45,
47, 48, 50, 60, 61), namely, hydrocephalus interna
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(Table 3); and skeletal malformations (Table 4). The
incidence of hydrocephalus interna produced by
DMEP (Table 3) was similar to that produced by
maternal zinc deficiency (51, 60, 61), although, in
general, its severity was much less.
Fetoplacental Metabolism of 14C-DMEP
Although no specific study has been reported
which identifies the nature ofDMEP or its metabo-
litesintheratfetusorplacenta, theresultsreported
here are in general agreement (28-32, 62) with the
metabolism of phthalates in nonpregnant rats as
obtained by using radiotracer techniques.
There is a relationship between teratogenicity
and carcinogenicity (63). Such a relationship for
DMEP, is not unequivocally established. Although
further studies are required to confirm whether or
not DMEP is a carcinogen, there are examples ofa
carcinogen havingteratogenic potential and aterato-
gen having carcinogenic potential (63). This is so
because congenital malformations occur through
genetic defects, or through embryotoxic effects on
prenatal development, orboth. For example, meth-
otrexate has carcinogenic properties and possesses
teratogenic potential, while 6-mercaptopurine, cy-
clophosphamide, and nitrosamides are teratogenic
and have carcinogenic potential (63). Several re-
searchers (3, 10, 12, 16, 26, 64, 65) have therefore
cautioned about the toxicity and possible health
threats ofphthalates.
Conclusions
The studies described here establish that the
maternal administration of dimethoxyethyl phtha-
late (DMEP) in a single dose during the organoge-
netic period (days 10-14) in the rat causes: (a)
embryopathic, fetotoxic andteratogeniceffects sev-
eral times higherthanreported by the widely stud-
ied plasticizer, diethylhexyl phthalate (DEHP); (b)
congenital deformities of the brain, such as hydro-
cephalus interna; (c) congenital skeletal malforma-
tions (66-96%), including multiple skeletal (14-64%)
and appendicular deformities (25-57%); (d) adverse
effects on maternal-fetal metabolism ofzinc; and (e)
teratogenicity, as mentioned above, due to DMEP
in the fetus.
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